This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries.
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
This generic protocol for ECDC studies describes the design and methods for a prospective multi-country cohort study of hospital-based healthcare workers (HCWs) to evaluate the effectiveness of COVID-19 vaccine in preventing laboratory-confirmed SARS-CoV-2 infection.
Influenza is a disease of public health importance due to the substantial seasonal morbidity and mortality and the high pandemic potential of its aetiologic agents, influenza viruses.
The European Respiratory Diseases Forecasting Hub (RespiCast) is open for weekly submission of several respiratory disease indicators such as influenza-like-illness, acute respiratory infection and COVID-19.
Several viral and bacterial respiratory pathogens are expected to continue co-circulating at variable levels during the coming months, and contribute to increased morbidity and mortality during this period. This is typical of every winter season.